Adamis Pharmaceuticals CorporationFind Ratings Reports
ADAMIS PHARMACEUTICALS CORP's gross profit margin for the second quarter of its fiscal year 2020 has significantly decreased when compared to the same period a year ago. Sales and net income fell significantly, underperforming compared to the average company in its subsector. ADAMIS PHARMACEUTICALS CORP has weak liquidity. Currently, the Quick Ratio is 0.75 which shows a lack of ability to cover short-term cash needs. The company's liquidity has increased from the same period last year.
At the same time, stockholders' equity ("net worth") has significantly decreased by 31.61% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is in a position in which financial difficulties could develop in the future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q2 FY20||Q2 FY19|
|Net Sales ($mil)||3.93||5.77|
|Net Income ($mil)||-11.26||-7.74|
|Balance Sheet||Q2 FY20||Q2 FY19|
|Cash & Equiv. ($mil)||7.89||4.09|
|Total Assets ($mil)||39.7||47.09|
|Total Debt ($mil)||7.0||4.49|
|Profitability||Q2 FY20||Q2 FY19|
|Gross Profit Margin||-19.28||36.41|
|Return on Assets||-86.18||-81.35|
|Return on Equity||-148.0||-113.31|
|Debt||Q2 FY20||Q2 FY19|
|Share Data||Q2 FY20||Q2 FY19|
|Shares outstanding (mil)||73.92||47.64|
|Div / share||0.0||0.0|
|Book value / share||0.31||0.71|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||6624369.0||2523751.0|
SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. To use another comparison, its price-to-book ratio of 2.91 indicates a discount versus the S&P 500 average of 3.76 and a significant discount versus the subsector average of 9.30. The price-to-sales ratio is well above the S&P 500 average, but well below the subsector average. After reviewing these and other key valuation criteria, ADAMIS PHARMACEUTICALS CORP proves to trade at a discount to investment alternatives.
|ADMP NM||Peers 28.15||ADMP NM||Peers 19.85|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
ADMP's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
ADMP's P/CF is negative making the measure meaningless.
|ADMP NM||Peers 18.14||ADMP NA||Peers 1.94|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
ADMP's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|ADMP 2.91||Peers 9.30||ADMP 38.56||Peers 17.58|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
ADMP is trading at a significant discount to its peers.
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
ADMP is expected to have an earnings growth rate that significantly exceeds its peers.
|ADMP 3.36||Peers 8.57||ADMP 7.36||Peers 7.77|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
ADMP is trading at a significant discount to its subsector on this measurement.
Average. Comparing a company's sales growth to its subsector helps to determine if the company is adding or losing market share.
ADMP is keeping pace with its peers on the basis of sales growth.